SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vakiener Victoria

(Last)

(First)

(Middle)

C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2020

3. Issuer Name and Ticker or Trading Symbol
Epizyme, Inc. [ EPZM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,867⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	11/25/2028	Common Stock	105,000	$7.6	D
Stock Option (Right to Buy)	⁽³⁾	01/23/2029	Common Stock	31,587	$9.12	D
Stock Option (Right to Buy)	⁽⁴⁾	02/02/2030	Common Stock	44,970	$21.39	D

Explanation of Responses:

1. Includes shares of Common Stock issuable under 12,775 restricted stock units ("RSUs") granted pursuant to the issuer's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. 3,425 RSUs are scheduled to vest in three equal annual installments on January 24, 2021, January 24, 2022 and January 24, 2023, and 9,350 RSUs are scheduled to vest in four equal annual installments on February 3, 2021, February 3, 2022, February 3, 2023 and February 3, 2024.

2. This option was granted on November 26, 2018 pursuant to the issuer's 2013 Stock Incentive Plan with respect to 105,000 shares of Common Stock, with 25% vesting on November 26, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

3. This option was granted on January 24, 2019 pursuant to the issuer's 2013 Stock Incentive Plan with respect to 31,587 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

4. This option was granted on February 3, 2020 pursuant to the issuer's 2013 Stock Incentive Plan with respect to 44,970 shares of Common Stock, with 25% vesting on February 3, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Exhibit Index: 24.1 Power of Attorney

	/s/ John Weidenbruch, attorney in fact	09/28/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.